Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The induction of a state of hypo-oestrogenism has been found to be effective in the treatment of endometriosis. Continued administration of agonistic analogues of luteinizing hormone-releasing hormone (LHRH) results in the normal menstruating female developing normogonadotrophic-amenorrhoea with reduced circulating levels of oestradiol-17B, often within the menopausal range. Uncontrolled studies reported the efficacy of LHRH analogues in patients with mild, moderate and even severe endometriosis (American Fertility Society classification) following 6 months therapy. A number of large multi-centre randomized open or double blind trials comparing various LHRH analogues against danazol are currently underway. Published results available to date indicate that LHRH analogues and danazol are equally effective at reducing the symptoms of endometriosis and inducing complete or partial resolution of endometriotic deposits. Side-effects are, however, more severe with danazol therapy. The side-effects experienced with LHRH analogues are those expected from an induced state of hypo-oestrogenism--hot flushes, dry vagina, headaches, superficial dyspareunia--but are well tolerated by patients. The alterations observed in bone and calcium metabolism are comparable to those in the menopause--increased Ca++ loss and reversible loss of trabecular bone density have been reported. These effects may limit the duration and/or frequency of LHRH analogue treatment regimens. The valuable role of LHRH analogues in the treatment of endometriosis has been established and, as newer formulations become available, they are likely to play an increasingly important part in patient management.
 ...
PMID:LHRH analogues in the treatment of endometriosis--comparative results with other treatments. 306 68

In response to a letter by Drs. D.M. and S.M. Hall calling loss of libido with oral contraceptive use only psychological, the author states it would seem that drugs which can produce an atrophic endometrium and a dry vagina might also cause loss or decrease of libido. The progestogenic low-estrogen compounds produce endometrial glands which have a high level of monoamine oxidase, particularly in the premenstrual phase. The author has found a correlation of depression and loss of libido with the endometrial monoamine oxidase activity. Estrogenic sequential regimens had a low incidence of depression and low monoamide oxidase activity. The Halls' data, with a much greater number of women under age 30, implies that oral contraceptives are not well tolerated by older women. Women under age 20 seem to be slower to have depression changes. Unmarried women may be more reluctant to admit to side effects because of their need for an efficient contraceptive. In the author's follow-up of 341 women, 40% noted mood changes and headaches on discontinuing oral contraceptives. Of 31 women stopping low-estrogen compounds 70% noted depressive mood changes.
 ...
PMID:Side effects of the pill. 472 23

In a placebo controlled randomized trial we evaluated the efficacy of melbrosia in women who suffered from severe menopausal symptoms. We could show that there was hardly no difference in the change of biochemical parameters, but we found out that the decrease of menopausal symptoms (headache, urinary incontinence, dry vagina, decreasing vitality) was significant in women who did undergo melbrosia medication compared to those who just took placebo. Due to our investigations we reasoned that melbrosia is especially appropriate to women who do not want and who do not need hormone replacement therapy, but who do suffer from menopausal symptoms.
 ...
PMID:[Placebo-controlled study of melbrosia in treatment of climacteric symptoms]. 777 Nov